Drug Trial Radar · NCT05537090
A Study to Assess Effect of BV100 on the Pharmacokinetics of Midazolam in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Sep 1, 2022
Primary completion
Jul 31, 2023
Study completion Sep 30, 2023
Sponsor
- Lead sponsor
- BioVersys AGIndustry
- Sponsor type
- Industry
- Collaborators
- Clinical Research Units Hungary
- First posted
- Sep 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To evaluate the effect of repeated doses of intravenous BV100 on the pharma-cokinetics of midazolam and 1-hydroxymidazolam.
Conditions
- Healthy Volunteers
Interventions
BV100Drug
Rifabutin for Infusion
MidazolamDrug
Syrup for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
- To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of midazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
- To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
- To evaluate the effect of repeated doses of intravenous BV100 on the pharmacokinetics of 1-hydroxymidazolamTime frame: 0 (predose) up to 24 hours postdose on Day 1 and Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRU Hungary Kft., Early Phase Unit
Kistarcsa, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.